Join us for our poster presentations to learn how our our cell-free HPV DNA assay can improve treatment monitoring for HPV-associated cancers!
November 13-16, 2024
San Diego, CA
aacr.org
Together for a better healthcare journey
We are committed to providing unwavering support to oncologists and clinical partners at every stage of the clinical drug development. Our aim is to deliver seamless end-to-end solutions without any compromises or unnecessary complexities. Our extensive portfolio includes a wide range of ultrasensitive NGS services in CLIA-validated lab with an exceptional project management team that sets us apart.
Poster Presentations
Analytical and clinical validation of HPV-SEQ, an NGS-based liquid biopsy platform for detection and quantification of human papilloma virus circulating tumor DNA.
Presented by: Samaneh Eickelschulte, Ph.D.
Sysmex Inostics GmbH, Hamburg, Germany
Cell-free HPV-DNA dynamics during induction chemotherapy and response-stratified de-escalation in viral-mediated oropharyngeal cancer.
Presented by: Dr. Ari Rosenberg
University of Chicago, Department of Medicine, Chicago, IL
Our assays
Our vast portfolio of molecular assays yields informative data from ctDNA & cfRNA samples, aiding in therapeutic monitoring biomarker identification.
cfHPV DNA Assay:
HPV-SEQ
With the ability to reliably and consistently detect as low as 2 copies of cfHPV-DNA, HPV-SEQ makes a powerful tool for surveillance and monitoring during development of cancer therapies for HPV driven cancers.
Broad Panel Assays:
Liquid Trace and Profile Plus Technology*
Our approach provides high sensitivity and specificity across a large set of genes. Our RNA capabilities go beyond fusion detection to include analyzing exon skipping, alternative splicing and gene expression.
Targeted Panel Assays:
Plasma-Safe-SeqS (PSS) Technology
Detecting low frequency somatic variants requires ultrasensitive liquid biopsy approaches. Our targeted approach balances the primary need for high sensitivity with the breadth of genomic coverage, providing confidence that somatic variants can be detected even at exceedingly low concentrations.